-

04:20:02 PM

ABT Stock News

ABT - Abbott Laboratories

09/28/22 9:00 AM

NYSE : ABT

earnings

Abbott Hosts Conference Call for Third-Quarter Earnings

Abbott (NYSE: ABT) will announce its third-quarter 2022 financial results on Wednesday, Oct. 19, 2022, before the market opens.The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m.

RHEA-AI

neutral

09/17/22 2:45 PM

NYSE : ABT

Late-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies

Five late-breaking presentations at TCT 2022 highlight the impact of Abbott's structural heart devices to repair or replace heart valves and close openings in the heart New data reinforce the safety and effectiveness of MitraClip(TM) for treating mitral regurgitation Results also demonstrate the

RHEA-AI

neutral

09/15/22 12:56 PM

NYSE : ABT

dividends

Abbott Declares 395th Consecutive Quarterly Dividend

The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 47 cents per share.This marks the 395 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2022, to

RHEA-AI

neutral

09/08/22 9:00 AM

NYSE : ABT

Three-Year Data on World's Smallest Heart Device Show Benefits of Fixing Holes in Newborn Hearts Without Surgery

Results reinforce that Amplatzer Piccolo(TM) Occluder is safe and effective for closing an opening in the heart known as a "patent ductus arteriosus" (PDA) in newborns Study found low adverse event rates following a Piccolo procedure, showing additional benefit of the device that can help babies avoid

RHEA-AI

negative

09/07/22 1:45 PM

Nasdaq, NYSE : ENOB, TSP, ABT

low float

LAWSUITS FILED AGAINST ENOB, TSP and ABT - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS

Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in

RHEA-AI

very negative

09/02/22 5:56 PM

NYSE : ABT

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Abbott Laboratories To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Abbott Laboratories ("Abbott Laboratories" or the "Company") (NYSE:ABT) and reminds investors of the October 31, 2022 deadline to seek the role of

RHEA-AI

very negative

08/29/22 9:00 AM

NYSE : ABT

New Data Show Abbott's HeartMate 3(TM) Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients

New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data 1 have shown survival for advanced heart failure patients who don't receive either a heart pump or heart transplant is less than

RHEA-AI

neutral

08/23/22 9:00 AM

NYSE : ABT

fda approval

FDA Approves Abbott's New Spinal Cord Stimulation Device; Provides Tailored Relief to Multiple Pain Areas and Adds More Treatment Options for Evolving Pain Conditions

Abbott's new Proclaim(TM) Plus spinal cord stimulation (SCS) system offers the next generation of stimulation therapy, giving physicians the ability to treat multi-site and evolving pain The system builds on the company's proprietary therapy, BurstDR(TM) stimulation, that works by mimicking natural

RHEA-AI

neutral

08/11/22 9:00 AM

NYSE : ABT

New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions

The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care Researchers used Abbott's i-STAT(TM) TBI Plasma test - the only FDA-cleared rapid test on a portable

RHEA-AI

negative

08/04/22 4:10 PM

NYSE : ABT

partnership

Abbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals

Two industry leaders join forces to empower people living with diabetes by providing information and insights to improve weight loss, glucose control and overall health Collaboration will create a seamless, integrated experience between Abbott's world-leading continuous glucose monitoring device 1

RHEA-AI

positive

1 2 3 4 5 6 7 8 9 10 Next